We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Johnson & Johnson Unit Defeated In Oxybutynin Case; Mylan To Produce Generic Version

Law360 (September 28, 2005, 12:00 AM EDT) -- In a stinging defeat for Johnson & Johnson’s Alza Corp., a federal court has ruled that Mylan’s generic version of the overactive bladder treatment Ditropan XL does not infringe on Alza’s...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.